June 10, 2021
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple MyelomaMay 27, 2021
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare ConferenceMay 13, 2021
CASI Pharmaceuticals Announces First Quarter 2021 Financial ResultsMay 11, 2021
CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021March 30, 2021
CASI Pharmaceuticals Announces Full Year 2020 Financial ResultsMarch 24, 2021
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common StockMarch 23, 2021
CASI Pharmaceuticals Announces Proposed Public Offering Of Common StockMarch 11, 2021
CASI Pharmaceuticals To Host Business Update Call March 12, 2021March 08, 2021
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China RegionFebruary 16, 2021
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business UpdatesJanuary 28, 2021
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma PatientsJanuary 21, 2021
CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin’s LymphomaJanuary 08, 2021
CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect ConferenceDecember 23, 2020
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy DesignationDecember 16, 2020
CASI Pharmaceuticals Announces Appointment Of Chief Financial OfficerNovember 18, 2020
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)November 09, 2020
CASI Pharmaceuticals Announces Third Quarter 2020 Financial ResultsNovember 05, 2020
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020October 27, 2020
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China regionOctober 02, 2020
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting
